Unicycive Therapeutics (UNCY) Cash from Operations (2020 - 2026)
Unicycive Therapeutics posted quarterly Cash from Operations of 6241000.0 for Q1 2026, up 29.9% year-on-year from 4804463.73 in Q1 2025, and up 22.3% on a QoQ basis from 8032000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Cash from Operations data on file, last reported at 6241000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 29.9% year-over-year to 6241000.0; the trailing twelve-month figure through Mar 2026 stood at 28655000.0 (up 7.63% YoY), and the FY2025 full-year result was 31317000.0, down 9.6% from the prior year.
- Cash from Operations for Q1 2026 stood at 6241000.0, up from 8032000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2957000.0 in Q1 2022 and bottomed at 9252000.0 in Q3 2024.
- The 5-year median for Cash from Operations is 6084000.0 (2022), against an average of 5886294.12.
- The widest annual swing landed in 2022, when Cash from Operations plunged 1304.15%; it then jumped 35.56% in 2025.
- A 5-year view of Cash from Operations shows it stood at 6084000.0 in 2022, then increased by 27.04% to 4439000.0 in 2023, then slumped by 47.51% to 6548000.0 in 2024, then slipped by 22.66% to 8032000.0 in 2025, then gained by 22.3% to 6241000.0 in 2026.
- The last three Cash from Operations figures came in at 6241000.0 (Q1 2026), 8032000.0 (Q4 2025), and 5962000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -6.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.24 Mn |
| Mar 31, 2026 | -6.24 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -6.55 Mn |
| Dec 31, 2024 | -6.55 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Jun 30, 2024 | -6.32 Mn |
| Jun 30, 2024 | -6.32 Mn |
| Mar 31, 2024 | -6.46 Mn |
| Mar 31, 2024 | -6.46 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Dec 31, 2023 | -4.44 Mn |
| Sep 30, 2023 | -4.42 Mn |
| Sep 30, 2023 | -4.42 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Jun 30, 2023 | -5.50 Mn |
| Mar 31, 2023 | -3.92 Mn |
| Mar 31, 2023 | -3.92 Mn |
| Dec 31, 2022 | -6.08 Mn |
| Dec 31, 2022 | -6.08 Mn |
| Sep 30, 2022 | -3.56 Mn |
| Sep 30, 2022 | -3.56 Mn |
| Jun 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -3.05 Mn |
| Mar 31, 2022 | -2.96 Mn |
| Mar 31, 2022 | -2.96 Mn |
| Dec 31, 2021 | -1.40 Mn |
| Dec 31, 2021 | -1.40 Mn |
| Sep 30, 2021 | -3.47 Mn |
| Sep 30, 2021 | -3.47 Mn |
| Jun 30, 2021 | -217,000.00 |
| Jun 30, 2021 | -217,000.00 |
| Mar 31, 2021 | -673,000.00 |
| Mar 31, 2021 | -673,000.00 |
| Dec 31, 2020 | -538,000.00 |
| Dec 31, 2020 | -538,000.00 |
| Sep 30, 2020 | -706,000.00 |
| Sep 30, 2020 | -706,000.00 |